Relmada Therapeutics, Inc. (RLMD)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.36
- As of
Kresmion compiles this page from RLMD's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
RELMADA THERAPEUTICS, INC. (RLMD): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
See the full RLMD dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RLMD on one page. Preview it with sample data, then open it live with a free account.
Preview the RLMD dossierActive signals for RLMD
- highCONSENSUS_BUY
3 tracked funds increased RLMD this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +832% to RLMD (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +8974% to RLMD (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 65% of RLMD (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in RLMD
FREE, NO ACCOUNT
Every signal on RLMD, as it fires
You are seeing 5 of 13 signals recorded on RLMD since 2026-05-24.
The five above landed across 2 days. The other 8 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RLMD (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 75955J402 · 2026Q2 | $16.3M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 75955J402 · 2026Q2 | $7.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 75955J402 · 2026Q2 | $1.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 75955J402 · 2026Q2 | $758K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 75955J402 · 2026Q2 | $400K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RLMD
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RLMD against its peers
RLMD's return on equity of -66.3% ranks in the 75th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | RLMD | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 33.5M | n/a | 15 |
| Operating margin | n/a | -296.2% | n/a | 14 |
| Net margin | n/a | -320.7% | n/a | 14 |
| Return on equity | -66.3% | -87.0% | 75 | 17 |
| 1 year | 66.3% | -7.8% | 78 | 19 |
Peers (21): EDIT, GALT, KYTX, TTRX, MYGN, EBS, FENC, IRD, SRZN, SPRY, ZURA, PROK, CCCC, OBIO, INDP, ENTA, DMAC, ARTV, YDES, PRTA, ENTX. Left out: TRXB (no annual filing), SCTX (no annual filing), EIKN (no annual filing), PRTC (period gap). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RLMD: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RLMD on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RLMD for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.